Recent Updates
Recently added Catalysts
BGM Negative Sentiment Score: 35/100

Qilian Received Notification of Deficiency from Nasdaq Related to not timely Filing of Annual Report Form 20-F

Key Takeaway: Qilian International Holding Group Ltd has been notified by Nasdaq of non-compliance due to its failure to timely file its annual report on Form 20-F. This notice does not have immediate effects on its listing or trading status. The company now has 60 days to submit a compliance plan, and if accepted, it may receive an extension of up to 180 days to resolve the issue. The company operates as a manufacturer and seller of various pharmaceutical and chemical products in China.

Market Sentiment Analysis

CONCERNS & RISKS

  • Failed to timely file annual report for the year ended September 30, 2022.
  • Received a notice of non-compliance from Nasdaq.
  • Subject to potential delisting if compliance is not regained.
  • 60 days given to submit a plan for compliance, adding pressure on the company.

Full Press Release Details

Qilian Received Notification of Deficiency from
Nasdaq Related to not timely Filing of Annual Report Form 20-F
JIUQUAN, China, February 23, 2023 /PRNewswire/
- Qilian International Holding Group Ltd (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical
and chemical products manufacturer, today announced it has received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq")
on February 16, 2023 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended September
30, 2022, Qilian is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports
with the Securities and Exchange Commission. This notice has no immediate effect on the listing or trading of Qilian's ordinary
Under Nasdaq's listing rules, the Company
has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar
days from the Company's Form 20-F's filing due date, or until August 14, 2023, to regain compliance.
About Qilian International Holding Group Ltd
Qilian International Holding Group Ltd, headquartered in Gansu, China,
is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice
products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers.
The Company's products are sold in more than 20 provinces in China. For more information, visit the Company's website at http://ir.qlsyy.net.
Forward-Looking Statements
This press release contains forward-looking
statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning
plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as "may, "will, "intend," "should,"
"believe," "expect," "anticipate," "project," "estimate" or similar expressions
that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees
of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the
following: the Company's goals and strategies; the Company's future business development; products demand and acceptance; changes
in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations
in general economic and business conditions in China; the COVID-19 outbreak and its impact on our operations and assumptions underlying
or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission.
For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press
release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available
for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the date hereof.

Frequently Asked Questions

What notice did Qilian receive from Nasdaq?

Qilian received a deficiency notice from Nasdaq for not timely filing its annual report.

What is the filing deadline for Qilian to regain compliance?

Qilian has 60 days to submit a compliance plan and up to 180 days to file the report.

What does Qilian International manufacture?

Qilian manufactures pharmaceutical and chemical products, including licorice and oxytetracycline.

Where does Qilian sell its products?

Qilian's products are sold in over 20 provinces throughout China.

Are Qilian's forward-looking statements guaranteed?

No, forward-looking statements come with risks and are not guarantees of future performance.

Last updated: Feb 23, 2023